Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
FDA Approves Rybrevant for Locally Advanced, Metastatic Epidermal Growth Factor
FDA approves J&J's Rybrevant with chemotherapy for EGFR-mutated NSCLC, reducing disease progression risk by 52%. Combination therapy showed median PFS of 6.3 months vs. 4.2 months with solo chemotherapy, and overall response rate of 53% vs. 29%. Common AEs included rash, infusion-related reactions, and fatigue.
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of ...
FDA approves Johnson & Johnson's Rybrevant in combination with chemotherapy for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R mutations, marking its third approval in 2024.
After July surge, FDA approvals for GI settle into summer lull: What you may have missed
After a July surge in FDA approvals for gastroenterology, including the first blood test for colorectal cancer, the agency saw a summer lull with only three GI approvals. Notable approvals included Skyrizi for UC and Crohn’s, a rapid HCV test for point-of-care use, and a third ustekinumab biosimilar.
FDA Approves Amivantamab for EGFR-Positive NSCLC With Exon 19 Deletion, Exon 21
FDA approves amivantamab-vmjw (Rybrevant) with chemotherapy for EGFR-mutated NSCLC progressing after EGFR TKI treatment. This combination is the only NCCN category 1 option for patients with multiple lesions after osimertinib failure. Phase 3 MARIPOSA-2 study showed improved progression-free survival and overall response rates compared to chemotherapy alone.
Related Clinical Trials:
FDA Approval Makes a Zevra Drug the First Therapy for Rare and Fatal Metabolic Disease
Zevra Therapeutics' drug, Miplyffa (acrimoclomol), is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), a fatal inherited metabolic disorder. The drug, taken three times daily, aims to slow NPC's progression, with FDA approval specifically for neurological effects. Miplyffa should be used with miglustat, and common side effects include upper respiratory tract infection, diarrhea, and weight loss. Zevra expects the drug to be available in the U.S. within 8-12 weeks.
The Role of Technology in Enhancing Diversity in Diabetes Clinical Trials
Technology enhances diversity in diabetes clinical trials by expanding outreach, simplifying participation, and improving data collection, leading to more inclusive and effective research outcomes.
Intravascular lithotripsy – a clinical trial snapshot
Intravascular lithotripsy (IVL) market is rapidly advancing, with Shockwave Medical's acquisition by Johnson & Johnson and recent catheter launch. Other companies like Amplitude Vascular Systems, Elixir Medical, FastWave Medical, and Bolt Medical are also progressing in clinical trials for their IVL technologies, focusing on safety and efficacy in treating calcified lesions.
J&J nets another key approval for blockbuster hope Rybrevant
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with chemotherapy in advanced NSCLC with EGFR exon 19 deletions or L858R mutations, following prior EGFR inhibitor treatment. The MARIPOSA-2 trial showed Rybrevant improved survival rates and progression-free survival compared to chemotherapy alone, though overall survival benefit was not yet statistically significant. Rybrevant aims to address resistance to third-generation EGFR inhibitors like AstraZeneca's Tagrisso.
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for ...
CHMP recommends daratumumab SC for newly diagnosed multiple myeloma eligible for ASCT, supported by PERSEUS study showing 60% reduction in risk of disease progression or death with quadruplet regimen.
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and ...
FDA approves RYBREVANT® (amivantamab-vmjw) with chemotherapy for advanced EGFR-mutated NSCLC, based on MARIPOSA-2 study showing 52% reduced risk of disease progression.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath